Ketorolac Tromethamine Injection, Solution
Product Images NDC 0404-9997

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 0404-9997). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

Chemical structure of Ketorolac tromethamine depicted as two connected molecular diagrams indicating the ketorolac and tromethamine components.*

FDA Label Image

Image1.jpg (Image1)

A pharmacokinetic data table showing average parameters (mean ± SD) for Ketorolac Tromethamine following oral, intramuscular, and intravenous doses at various strengths (10 mg to 60 mg). It includes bioavailability, Tmax, Cmax, Cmin, and Cavg values with units and dosing conditions for single-dose and steady-state measurements.*

FDA Label Image

Image2.jpg (Image2)

A pharmacokinetic data table showing percentages of Ketorolac tromethamine dose metabolized and excreted in feces and urine, plasma protein binding, and various plasma concentration parameters. It includes footnotes detailing the study types and volunteer numbers used to derive the data, as well as simulation explanations for mean values and standard deviations.*

FDA Label Image

Image3.jpg (Image3)

A data table titled 'The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac Tromethamine (Intramuscular and Oral) in Adult Populations.' It presents total clearance values in L/h/kg and terminal half-life in hours for intramuscular and oral administration across different subject groups, including normal subjects, healthy elderly subjects, patients with hepatic dysfunction, patients with renal impairment, and renal dialysis patients.*

FDA Label Image

Image4.jpg (Image4)

A table listing adverse experiences associated with Ketorolac tromethamine injection. It categorizes gastrointestinal symptoms including abdominal pain, constipation, dyspepsia, flatulence, GI fullness, ulcers, heartburn, nausea, stomatitis, and vomiting. Additional side effects include abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating.*

FDA Label Image

Image5.jpg (Image5)

A data table detailing the incidence of clinically serious gastrointestinal bleeding related to age, total daily dose, and history of gastrointestinal perforation, ulcer, or bleeding (PUB) during up to 5 days of treatment with Ketorolac Tromethamine Injection. The table separates data for adult patients with and without a history of PUB, categorizing incidence percentages by age group (<65 years and ≥65 years) and total daily dose ranges (<60 mg, 60-90 mg, 90-120 mg, >120 mg).*

FDA Label Image

Label1.jpg (Label1)

Label for Ketorolac tromethamine injection, USP 30 mg/mL in a 2 mL single-dose vial for intramuscular use. The label includes instructions for storage at 20 to 25°C, protection from light, and keeping out of children's reach. It is packaged by Henry Schein, Inc., Bastian, VA, and displays the NDC 0404-9997-02 along with lot and expiration placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.